CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG)

BACKGROUND: D2C7 immunotoxin (D2C7-IT) is a dual-specific recombinant immunotoxin comprising an EGFR-wt and mutant-specific (EGFRvIII) monoclonal antibody fragment and a genetically engineered form of the pseudomonas exotoxin. When injected directly into the tumor mass by convection enhanced deliver...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Desjardins, Annick, Randazzo, Dina, Chandramohan, Vidya, Peters, Katherine, Johnson, Margaret, Landi, Daniel, Khasraw, Mustafa, Threatt, Stevie, Bullock, Chevelle, Herndon, James, Lipp, Eric, Sampson, John, Friedman, Allan, Friedman, Henry, Ashley, David, Bigner, Darell
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Trials: Immunologic
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650440/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.157
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados